12,372 trials
Complicated Intra-Abdominal Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA). — 337; 349; 37; 30…
Varicella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL — 97.2; 97.2…
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died During the Overall Study — 73.2; 75.2 percentage of participants
Anemia
Primary: Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period — -0.10; 0.01; -0.10 gram per deciliter (g/dL) — p=<0.0001
Non-Squamous Cell Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint — 12.19; 9.36 Months — p=0.0015
Acne
Primary: Reduction of Undesirable Effects — 26; 38; 35; 10 participants — p=0.001
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Mean St.George's Respiratory Questionnaire (SGRQ) Total Score at Day 84 — -2.12; -6.15 Score on scale — p=<0.001
Autism
Primary: Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6 — 8.8; 9.4; 7.5 units on a scale — p=0.5463
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Visit 8) — 0.074; -0.014 Liters — p=<0.001
Melanoma
Primary: Overall Survival (OS) — NA; 10.84 Months — p=<0.0001
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm — 233; 245 Participants
Rotator Cuff Syndrome · Shoulder Bursitis
Primary: Change From Baseline in Abduction Rotation Pain VAS at Visit 5 (Day 22) (Traumeel® S Injections Versus Fortecortin) for Active External Rotation — -18.7; -27.2 units on…
Colorectal Cancer
Primary: Progression Free Survival — 154; 168 days — p=0.00584
Epilepsy · Monotherapy
Primary: Proportion of Subjects in the Full Analysis Set (FAS) Remaining Seizure Free for 6 Consecutive Months (26 Consecutive Weeks) of Treatment Following Stabilization at the…
Healthy
Primary: Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite…